Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
Recruiting now · Phase 1/Phase 2
Conditions studied: Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
In brief
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined Novartis-sponsored opnurasib studies and to continue to assess safety in these participants.
Key facts
- Study ID
- NCT07468071
- Run by
- Novartis Pharmaceuticals
- People needed
- 40
- Starts
- 2026-06-08
- Expected to finish
- 2029-09-17
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Sint-Niklaas, Oost Vlaanderen, Belgium (enrolling)
- Novartis Investigative Site — Montreal, Quebec, Canada (enrolling)
- Novartis Investigative Site — Guangzhou, Guangdong, China (enrolling)
- Novartis Investigative Site — Kashiwa, Chiba, Japan (enrolling)
- Novartis Investigative Site — Koto Ku, Tokyo, Japan (enrolling)
- Novartis Investigative Site — Kuching, Sarawak, Malaysia (enrolling)
- Novartis Investigative Site — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.